KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Gilead Sciences (GILD) Short-Term Debt issuances (2012)

Gilead Sciences posted quarterly Short-Term Debt issuances of $149.0 million for Q3 2012, down 85.07% on a QoQ basis from $997.9 million in Q1 2012.

Gilead Sciences (GILD) has 1 years of Short-Term Debt issuances data on file, last reported at $149.0 million in Q3 2012.

  • For the quarter ending Q3 2012, Short-Term Debt issuances changed N/A year-over-year to $149.0 million; the trailing twelve-month figure through Sep 2012 stood at $1.1 billion (changed N/A YoY), and the FY2010 full-year result was $500.0 million, up 25.0% from the prior year.
  • Short-Term Debt issuances for Q3 2012 stood at $149.0 million, down from $997.9 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $997.9 million in Q1 2012 and bottomed at $149.0 million in Q3 2012.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 1.78 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 12.44 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -499.00 Mn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 1.06 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn -
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -127.00 Mn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 321.00 Mn
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Sep 30, 2012 148.96 Mn
Sep 30, 2012 148.96 Mn
Mar 31, 2012 997.89 Mn
Mar 31, 2012 997.89 Mn